Type 2 Diabetes Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036

Market Overview:

The type 2 diabetes market reached a value of USD 27.6 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2025. Looking forward, IMARC Group expects the top 7 major markets to reach USD 48.6 Billion by 2036, exhibiting a growth rate (CAGR) of 5.80% during 2026-2036.

The type 2 diabetes market has been comprehensively analyzed in IMARC's new report titled "Type 2 Diabetes Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2026-2036". Type 2 diabetes refers to a chronic metabolic disorder that develops when the body becomes insulin resistant or cannot produce enough insulin to maintain normal blood glucose levels. The symptoms can be mild or go unnoticed for years. However, some common indications include increased thirst and urination, fatigue, blurred vision, slow-healing wounds or infections, tingling or numbness in the feet or hands, etc. In many cases, people with type 2 diabetes may experience frequent yeast infections or darkened skin areas, particularly in the neck, armpits, groin, etc. The diagnosis of the ailment typically involves a series of blood investigations that evaluate the levels of glucose in the bloodstream. The most common test is the fasting plasma glucose test, which analyzes blood sugar levels after an overnight fast. Another procedure is the A1C test that assesses the average blood sugar level over the past two to three months. In some cases, a random blood sugar test or an oral glucose tolerance test may be used to confirm the diagnosis.

To get more information on this market Request Sample

The rising cases of insulin resistance, which prevents glucose from entering the cells and being utilized for energy, are primarily driving the type 2 diabetes market. In addition to this, the increasing incidences of various risk factors, such as a diet rich in sugar and processed foods, high blood pressure, a family history of diabetes, certain medical conditions like polycystic ovary syndrome (PCOS), etc., are also bolstering the market growth. Moreover, the widespread adoption of several oral medications, including metformin, sulfonylureas, meglitinides, DPP-4 inhibitors, etc., to lower blood sugar levels is acting as another significant growth-inducing factor. Besides this, the emerging popularity of non-invasive procedures, such as the oral glucose tolerance test (OGTT) and the intravenous glucose tolerance test (IVGTT), on account of their numerous associated benefits, including reduced risk of infection, high convenience, potential for early disease detection, etc., is also creating a positive outlook for the market. Furthermore, the escalating utilization of smart insulin, which automatically activates in response to high blood sugar levels and deactivates when the levels return to normal, for reducing the likelihood of hypoglycemia and improving disease management, is expected to drive the type 2 diabetes market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the type 2 diabetes market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for type 2 diabetes and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the type 2 diabetes market in any manner.

Recent Developments:

• In March 2026, Orforglipron, the oral GLP-1 receptor agonist developed by Eli Lilly and Company, is currently under regulatory review, with an expected FDA decision around April 2026. This marks a critical inflection point not only for Lilly’s pipeline but also for the broader Type 2 diabetes and obesity treatment landscape. If approved, orforglipron would become the first small-molecule (non-peptide) oral GLP-1 therapy, differentiating it from existing GLP-1 drugs that are either injectable (like Ozempic) or peptide-based oral formulations.
• In March 2026, Retatrutide, an investigational therapy from Eli Lilly, has demonstrated significant weight loss potential in its Phase 3 TRIUMPH clinical program, reinforcing its position as one of the most promising next-generation treatments for obesity and type.
• In February 2025, Oramed Pharmaceuticals Inc. has announced plans to spin off its proprietary oral insulin and Protein Oral Delivery (POD™) technology into a newly formed joint venture, OraTech Pharmaceuticals, in partnership with Hefei Tianhui Biotech Co., Ltd. (HTIT). The strategic move is aimed at accelerating the development and commercialization of oral insulin therapies, particularly Oramed’s lead candidate, ORMD-0801, designed for the treatment of Type 2 diabetes.

Key Highlights:

• Research conducted in Delhi and the southern city of Chennai found that inhaling air with high amounts of PM2.5 particles led to high blood sugar levels and increased type 2 diabetes incidence.
• Around 18.7 million of the 537 million population with diabetes in the world live in low- and middle-income countries (LMIC), where there is also a rise in the number of adolescents, children, and young adults identified with type 2 diabetes.
• About 25 percent of those with diabetes onset under 25 have type 2 diabetes.
• A recent genetic study by UK scientists reveals that depression may be an immediate trigger of type 2 diabetes, which could help to prevent the disease.
• A study published in JAMA Network Open found that rates of new-onset type 2 diabetes increased by 62% among US youngsters after the COVID-19 pandemic began, particularly among Black and Hispanic children.

Drugs:

Steglatro (Ertugliflozin) is a sodium/glucose cotransporter 2 (SGLT2) inhibitor utilized to treat type 2 diabetes. It acts by decreasing renal reabsorption of filtered glucose and lowering the renal glucose threshold, resulting in increased urine glucose excretion in adults with type 2 diabetes.

Time Period of the Study

• Base Year: 2025
• Historical Period: 2020-2025
• Market Forecast: 2026-2036

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Type 2 diabetes market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Type 2 diabetes market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current Type 2 diabetes marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the Type 2 Diabetes market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2025 and how are they expected to perform till 2036?
• What was the country-wise size of the Type 2 Diabetes across the seven major markets in 2025 and what will it look like in 2036?
• What is the growth rate of the Type 2 Diabetes across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of prevalent cases (2020-2036) of Type 2 Diabetes across the seven major markets?
• What is the number of prevalent cases (2020-2036) of Type 2 Diabetes by age across the seven major markets?
• What is the number of prevalent cases (2020-2036) of Type 2 Diabetes by gender across the seven major markets?
• What is the number of prevalent cases (2020-2036) of Type 2 Diabetes by type across the seven major markets?
• How many patients are diagnosed (2020-2036) with Type 2 Diabetes across the seven major markets?
• What is the size of the Type 2 Diabetes’ patient pool (2020-2025) across the seven major markets?
• What would be the forecasted patient pool (2026-2036) across the seven major markets?
• What are the key factors driving the epidemiological trend of Type 2 Diabetes?
• What will be the growth rate of patients across the seven major markets?

Type 2 Diabetes: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for Type 2 Diabetes drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Type 2 Diabetes market?
• What are the key regulatory events related to the Type 2 Diabetes market?
• What is the structure of clinical trial landscape by status related to the Type 2 Diabetes market?
• What is the structure of clinical trial landscape by phase related to the Type 2 Diabetes market?
• What is the structure of clinical trial landscape by route of administration related to the Type 2 Diabetes market?